Jacob Fredsøe1,2, Anne K I Rasmussen3, Emma B Laursen1,2, Yunpeng Cai4, Kenneth A Howard4, Bodil G Pedersen2,5, Michael Borre2,6, Peter Mouritzen3, Torben Ørntoft1,2, Karina D Sørensen7,2. 1. Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. 2. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. 3. Exiqon A/S, Vedbaek, Denmark. 4. Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark. 5. Department of Radiology, Aarhus University Hospital, Aarhus, Denmark. 6. Department of Urology, Aarhus University Hospital, Aarhus, Denmark. 7. Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; kdso@clin.au.dk.
Abstract
BACKGROUND: Detection of prostate cancer (PC) based on serum prostate-specific antigen (PSA) testing leads to many unnecessary prostate biopsies, overdiagnosis, and overtreatment of clinically insignificant tumors. Thus, novel and more accurate molecular biomarkers are required. METHODS: Using reverse transcription quantitative PCR, we measured the concentrations of 45 preselected microRNAs (miRNAs) in extracellular vesicle-enriched cell-free urine samples from 4 independent patient cohorts from Spain and Denmark, including 758 patients with clinically localized PC, 289 noncancer controls with benign prostatic hyperplasia (BPH), and 233 patients undergoing initial transrectal ultrasound (TRUS)-guided prostate biopsy owing to PC suspicion (101 with benign and 132 with malignant outcome). Diagnostic potential was assessed by ROC and decision curve analysis. RESULTS: We identified and successfully validated 8 upregulated and 21 downregulated miRNAs in urine from PC patients. Furthermore, we validated a previously identified 3-miRNA diagnostic ratio model, uCaP (miR-222-3p*miR-24-3p/miR-30c-5p). High uCaP scores were distinctive of PC in urine samples from BPH vs PC patients in 3 independent cohorts [area under the curve (AUC) = 0.84, 0.71, 0.72]. Additionally, uCaP predicted TRUS biopsy results with greater accuracy than PSA (AUC uCaP = 0.644; AUC PSA = 0.527) for patients within the diagnostic gray zone (PSA ≤ 10 ng/mL). CONCLUSIONS: We successfully validated a urine-based diagnostic 3-miRNA signature for PC (uCaP) in 3 independent patient cohorts from 2 countries. In the future, the simple and noninvasive uCaP test may be used to help more accurately select patients for prostate biopsy. Prospective clinical validation is warranted.
BACKGROUND: Detection of prostate cancer (PC) based on serum prostate-specific antigen (PSA) testing leads to many unnecessary prostate biopsies, overdiagnosis, and overtreatment of clinically insignificant tumors. Thus, novel and more accurate molecular biomarkers are required. METHODS: Using reverse transcription quantitative PCR, we measured the concentrations of 45 preselected microRNAs (miRNAs) in extracellular vesicle-enriched cell-free urine samples from 4 independent patient cohorts from Spain and Denmark, including 758 patients with clinically localized PC, 289 noncancer controls with benign prostatic hyperplasia (BPH), and 233 patients undergoing initial transrectal ultrasound (TRUS)-guided prostate biopsy owing to PC suspicion (101 with benign and 132 with malignant outcome). Diagnostic potential was assessed by ROC and decision curve analysis. RESULTS: We identified and successfully validated 8 upregulated and 21 downregulated miRNAs in urine from PC patients. Furthermore, we validated a previously identified 3-miRNA diagnostic ratio model, uCaP (miR-222-3p*miR-24-3p/miR-30c-5p). High uCaP scores were distinctive of PC in urine samples from BPH vs PC patients in 3 independent cohorts [area under the curve (AUC) = 0.84, 0.71, 0.72]. Additionally, uCaP predicted TRUS biopsy results with greater accuracy than PSA (AUC uCaP = 0.644; AUC PSA = 0.527) for patients within the diagnostic gray zone (PSA ≤ 10 ng/mL). CONCLUSIONS: We successfully validated a urine-based diagnostic 3-miRNA signature for PC (uCaP) in 3 independent patient cohorts from 2 countries. In the future, the simple and noninvasive uCaP test may be used to help more accurately select patients for prostate biopsy. Prospective clinical validation is warranted.
Authors: Yoko Koh; Matias A Bustos; Jamie Moon; Rebecca Gross; Romela Irene Ramos; Suyeon Ryu; Jane Choe; Selena Y Lin; Warren M Allen; David L Krasne; Timothy G Wilson; Dave S B Hoon Journal: Cancers (Basel) Date: 2022-05-12 Impact factor: 6.575
Authors: Maria Yu Konoshenko; Evgeniy A Lekchnov; Olga E Bryzgunova; Ivan A Zaporozhchenko; Sergey V Yarmoschuk; Oksana A Pashkovskaya; Svetlana V Pak; Pavel P Laktionov Journal: Diagnostics (Basel) Date: 2020-01-10
Authors: Anson Ku; Jacob Fredsøe; Karina D Sørensen; Michael Borre; Mikael Evander; Thomas Laurell; Hans Lilja; Yvonne Ceder Journal: Front Oncol Date: 2021-03-25 Impact factor: 6.244
Authors: Jacob Fredsøe; Martin Rasmussen; Amy L Tin; Andrew J Vickers; Michael Borre; Karina D Sørensen; Hans Lilja Journal: Sci Rep Date: 2022-09-07 Impact factor: 4.996
Authors: Jacob Fredsøe; Anne K I Rasmussen; Peter Mouritzen; Marianne T Bjerre; Peter Østergren; Mikkel Fode; Michael Borre; Karina D Sørensen Journal: Diagnostics (Basel) Date: 2020-03-28